# US 2020/0390692 A1 · Apparatus and formulations for suprachoroidal drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390692 A1
- Document ID: US20200390692A1
- Status: Published application
- Kind: A1
- Application number: 16/741,473
- Filed: 2020-01-13
- Published: 2020-12-17
- Earliest claimed: 2006-02-22
- Assignees: Clearside Biomedical, Inc.
- Applicants: Clearside Biomedical, Inc.
- Inventors: Ronald YAMAMOTO; Stanley R. CONSTON; David SIERRA
- Web page: https://patentgrep.com/patent/US20200390692A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61F 9/0026: {Ophthalmic product dispenser attachments to facilitate positioning near the eye}
- A61F 9/007: Methods or devices for eye surgery
- A61F 9/00736: {Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments (A61F9/008 takes precedence)}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/717: Celluloses
- A61K 31/718: Starch or degraded starch, e.g. amylose, amylopectin
- A61K 31/722: Chitin, chitosan
- A61K 31/728: Hyaluronic acid
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61M 5/486: {Indicating injection pressure}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61M 2005/3103: {Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle}
- A61M 2210/0612: Eyes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

## Claims

### Claim 1

A drug formulation characterized by a zero shear viscosity of at least 300,000 mPas for injection into the suprachoroidal space of an eye comprising a biologically active substance and a thixotropic polymeric excipient that acts as a gel-like material to spread after injection and uniformly distribute and localize the drug in a region of the suprachoroidal space.

### Claim 2 (depends on 1)

The drug formulation according to claim 1 further characterized by a viscosity of not more than about 400 mPas at 1000 s-1 shear rate.

### Claim 3 (depends on 1)

The drug formulation according to claim 1 wherein said gel-like material crosslinks after injection into the suprachoroidal space.

### Claim 4 (depends on 1)

The drug formulation according to claim 1 wherein said biologically active substance comprises microparticles or microspheres.

### Claim 5 (depends on 1)

The drug formulation according to claim 1 wherein said polymeric excipient comprises hyaluronic acid, chondroitin sulfate, gelatin, polyhydroxyethylmethacrylate, dermatin sulfate, polyethylene oxide, polyethylene glycol, polypropylene oxide, polypropylene glycol, alginate, starch derivatives, a water soluble chitin derivative, a water soluble cellulose derivative or polyvinylpyrollidone.

### Claim at position 6

-9. (canceled)

### Claim 10 (depends on 1)

The drug formulation according to claim 1 wherein the biologically active substance comprises an antibiotic, a steroid, a non-steroidal anti-inflammatory agent, a neuroprotectant, an anti-VEGF agent, or a neovascularization suppressant.

### Claim 11 (depends on 10)

The drug formulation of claim 10 wherein the biologically active substance comprises both a steroid and an anti-VEGF agent or neovascular suppressant.

### Claim 12

A device for minimally invasive delivery of a drug formulation into the suprachoroidal space of the eye comprising a needle having a leading tip shaped to allow passage through scleral tissues without damage to the underlying choroidal tissues, and a sensor to guide placement of said tip to deliver said formulation adjacent to or within the suprachoroidal space.

### Claim 13 (depends on 12)

The device according to claim 12 wherein said sensor provides an image of the scleral tissues.

### Claim 14 (depends on 12)

The device of claim 12 wherein said sensor responds to ultrasound, light, or differential pressure.

### Claim 15 (depends on 12)

The device of claim 12, further comprising an inner tip that provides an inward distending action to the choroid upon contacting the choroid to prevent trauma thereto.

### Claim 16 (depends on 12)

The device according to claim 12, further containing a drug formulation comprising a polymeric excipient and a biologically active substance.

### Claim 17 (depends on 12)

The device according to claim 12, further comprising a flange to seal the interface between the needle and the interposing tissues.

### Claim 18 (depends on 12)

The device according to claim 12, further comprising an angled stop plate located on said device to interface with the outer surface of the eye and set the depth and angle of penetration of said leading tip relative to the eye surface.

### Claim at position 16

-21. (canceled)

### Claim 22

A method for administering drugs to a posterior region of the eye comprising placing a formulation comprising a biologically active substance comprising microspheres or microparticles with an outer diameter in the range of about 1 to 33 microns in an anterior region of the suprachoroidal space such that said microspheres or microparticles subsequently migrate to said posterior region.

### Claim 23 (depends on 22)

The method according to claim 22 wherein said formulation comprises a polymer excipient to uniformly disperse the microparticles or microspheres in the suprachoroidal space.

### Claim 24

(canceled)

### Claim 25 (depends on 22)

The method according to claim 22 wherein said formulation comprises a thixotropic polymer.
